Complete remission of OC-resistant catamenial shoulder joint pain and inguinal pain associated with extraperitoneal endometriosis following personalized GnRH agonist therapy.

Abstract

BACKGROUND:

Patients with severe extraperitoneal endometriosis require rapid remission and cannot wait for the effects of oral contraceptive hormones (OCs) to appear.

CASE:

We successfully achieved personalized gonadotropin-releasing hormone agonist (GnRHa) therapy for a patient with catamenial right shoulder joint pain and right inguinal pain associated with extraperitoneal endometriosis, which was completely unable to be suppressed by OCs. A total of 15 subcutaneous GnRHa depot injections over a period of 19 months was performed according to the serum estradiol and LH levels, in order to maintain long-term amenorrhea without any estrogen-deprivation effects. No recurrence of the catamenial symptoms has been observed for more than 35 months after the final GnRHa depot injection.

CONCLUSION:

Personalized GnRHa therapy should become the first-choice therapy for OC-resistant inoperable extraperitoneal endometriosis.

• Authors: T Tanaka, N Umesaki
• Journal: Clinical and experimental obstetrics & gynecology (Clin Exp Obstet Gynecol) Vol. 36 Issue 1 Pg. 46-8 ( 2009) ISSN: 0390-6663 [Print] Singapore
• PMID: 19400418 (Publication Type: Case Reports, Journal Article)

Chemical References

• Fertility Agents, Female
• Gonadotropin-Releasing Hormone
• Leuprolide

Topics

• Endometriosis (complications, drug therapy, pathology)
• Female
• Fertility Agents, Female (administration & dosage)
• Gonadotropin-Releasing Hormone (agonists)
• Humans
• Inguinal Canal (pathology)
• Injections, Subcutaneous
• Leuprolide (administration & dosage)
• Middle Aged
• Shoulder Pain (drug therapy, etiology)